Histamine dihydrochloride administration has been approved in Europe for the treatment of acute myeloid leukaemia, used in combination with the immunotherapeutic agent IL-2, a fact that encourages the study of this biogenic amine as an adjuvant to therapeutic approaches for other cancers.24,25. The gene discussed is IL2; the disease is acute myeloid leukemia.